Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer

Wei Chih Su; Yi Chen Tsai; Hsiang Lin Tsai; Tsung Kun Chang; Tzu Chieh Yin; Ching Wen Huang; Yen Cheng Chen; Ching Chun Li; Po Jung Chen; Yun Ru Liu; Tsung Han Hsieh; Jaw Yuan Wang

doi:10.3390/cimb44040106

Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer

Wei Chih Su, Yi Chen Tsai, Hsiang Lin Tsai, Tsung Kun Chang, Tzu Chieh Yin, Ching Wen Huang, Yen Cheng Chen, Ching Chun Li, Po Jung Chen, Yun Ru Liu, Tsung Han Hsieh, Jaw Yuan Wang

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Personalized treatments based on the genetic profiles of tumors can simultaneously optimize efficacy and minimize toxicity, which is beneficial for improving patient outcomes. This study aimed to integrate gene alterations associated with predictive and prognostic outcomes in patients with metastatic colorectal cancer (mCRC) with polymerase chain reaction (PCR) and in‐house nextgeneration sequencing (NGS) to detect KRAS, NRAS, and BRAF mutations. In the present study, 41 patients with mCRC were assessed between August 2017 and June 2019 at a single institution. The overall concordance between NGS and PCR results for detecting KRAS, NRAS, and BRAF mutations was considerably high (87.8–92.7%), with only 15 discrepant results between PCR and NGS. Our companion diagnostic test analyzes KRAS, NRAS, and BRAF as a panel of CRC molecular targets; therefore, it has the advantages of requiring fewer specimens and being more time and cost efficient than conventional testing for separate analyses, allowing for the simultaneous analysis of multiple genes.

Original language	English
Article number	1563
Journal	Current Issues in Molecular Biology
Volume	44
Issue number	4
DOIs	https://doi.org/10.3390/cimb44040106
Publication status	Published - Apr 2022

Keywords

metastatic colorectal cancer
next‐generation sequencing
polymerase chain reaction

ASJC Scopus subject areas

Microbiology
Molecular Biology
Microbiology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cimb44040106

Cite this

Su, W. C., Tsai, Y. C., Tsai, H. L., Chang, T. K., Yin, T. C., Huang, C. W., Chen, Y. C., Li, C. C., Chen, P. J., Liu, Y. R., Hsieh, T. H., & Wang, J. Y. (2022). Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer. Current Issues in Molecular Biology, 44(4), Article 1563. https://doi.org/10.3390/cimb44040106

Su, WC, Tsai, YC, Tsai, HL, Chang, TK, Yin, TC, Huang, CW, Chen, YC, Li, CC, Chen, PJ, Liu, YR , Hsieh, TH & Wang, JY 2022, 'Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer', Current Issues in Molecular Biology, vol. 44, no. 4, 1563. https://doi.org/10.3390/cimb44040106

@article{2b62024bd5184242abcce93289e943a9,

title = "Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer",

abstract = "Personalized treatments based on the genetic profiles of tumors can simultaneously optimize efficacy and minimize toxicity, which is beneficial for improving patient outcomes. This study aimed to integrate gene alterations associated with predictive and prognostic outcomes in patients with metastatic colorectal cancer (mCRC) with polymerase chain reaction (PCR) and in‐house nextgeneration sequencing (NGS) to detect KRAS, NRAS, and BRAF mutations. In the present study, 41 patients with mCRC were assessed between August 2017 and June 2019 at a single institution. The overall concordance between NGS and PCR results for detecting KRAS, NRAS, and BRAF mutations was considerably high (87.8–92.7%), with only 15 discrepant results between PCR and NGS. Our companion diagnostic test analyzes KRAS, NRAS, and BRAF as a panel of CRC molecular targets; therefore, it has the advantages of requiring fewer specimens and being more time and cost efficient than conventional testing for separate analyses, allowing for the simultaneous analysis of multiple genes.",

keywords = "metastatic colorectal cancer, next‐generation sequencing, polymerase chain reaction",

author = "Su, {Wei Chih} and Tsai, {Yi Chen} and Tsai, {Hsiang Lin} and Chang, {Tsung Kun} and Yin, {Tzu Chieh} and Huang, {Ching Wen} and Chen, {Yen Cheng} and Li, {Ching Chun} and Chen, {Po Jung} and Liu, {Yun Ru} and Hsieh, {Tsung Han} and Wang, {Jaw Yuan}",

note = "Funding Information: Funding: This work was supported by grants through funding from the Ministry of Science and Technology (MOST 109‐2314‐B‐037‐035, MOST 109‐2314‐B‐037‐040, MOST 109‐2314‐B‐037‐046‐ MY3, MOST110‐2314‐B‐037‐097) and the Ministry of Health and Welfare (MOHW109‐TDU‐B‐212‐ 134026, MOHW109‐TDU‐B‐212‐114006, MOHW110‐TDU‐B‐212‐1140026), and funded by the health and welfare surcharge on tobacco products, and the Kaohsiung Medical University Hospital (KMUH110‐0R37, KMUH110‐0R38, KMUH110‐0M34, KMUH110‐0M35, KMUH110‐0M36, KMUH109‐9M32, KMUH108‐8M35, KMUH106‐6M30, KMUH105‐5M21, KMUH104‐4M25, KMU‐ HSA11013, KMUH‐DK(C)110010, KMUH‐DK(B)110004‐3), KMU Center for Cancer Research (KMU‐TC111A04‐1), KMU Center for Liquid Biopsy and Cohort Research Center Grant (KMU‐ TC109B05), and KMU Office for Industry–Academic Collaboration (S109036), Kaohsiung Medical University. In addition, this study was supported by the Grant of Taiwan Precision Medicine Initi‐ ative, Academia Sinica, Taiwan, R.O.C. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = apr,

doi = "10.3390/cimb44040106",

language = "English",

volume = "44",

journal = "Current Issues in Molecular Biology",

issn = "1467-3037",

publisher = "Caister Academic Press",

number = "4",

}

TY - JOUR

T1 - Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer

AU - Su, Wei Chih

AU - Tsai, Yi Chen

AU - Tsai, Hsiang Lin

AU - Chang, Tsung Kun

AU - Yin, Tzu Chieh

AU - Huang, Ching Wen

AU - Chen, Yen Cheng

AU - Li, Ching Chun

AU - Chen, Po Jung

AU - Liu, Yun Ru

AU - Hsieh, Tsung Han

AU - Wang, Jaw Yuan

N1 - Funding Information: Funding: This work was supported by grants through funding from the Ministry of Science and Technology (MOST 109‐2314‐B‐037‐035, MOST 109‐2314‐B‐037‐040, MOST 109‐2314‐B‐037‐046‐ MY3, MOST110‐2314‐B‐037‐097) and the Ministry of Health and Welfare (MOHW109‐TDU‐B‐212‐ 134026, MOHW109‐TDU‐B‐212‐114006, MOHW110‐TDU‐B‐212‐1140026), and funded by the health and welfare surcharge on tobacco products, and the Kaohsiung Medical University Hospital (KMUH110‐0R37, KMUH110‐0R38, KMUH110‐0M34, KMUH110‐0M35, KMUH110‐0M36, KMUH109‐9M32, KMUH108‐8M35, KMUH106‐6M30, KMUH105‐5M21, KMUH104‐4M25, KMU‐ HSA11013, KMUH‐DK(C)110010, KMUH‐DK(B)110004‐3), KMU Center for Cancer Research (KMU‐TC111A04‐1), KMU Center for Liquid Biopsy and Cohort Research Center Grant (KMU‐ TC109B05), and KMU Office for Industry–Academic Collaboration (S109036), Kaohsiung Medical University. In addition, this study was supported by the Grant of Taiwan Precision Medicine Initi‐ ative, Academia Sinica, Taiwan, R.O.C. Publisher Copyright: © 2022 by the authors.

PY - 2022/4

Y1 - 2022/4

N2 - Personalized treatments based on the genetic profiles of tumors can simultaneously optimize efficacy and minimize toxicity, which is beneficial for improving patient outcomes. This study aimed to integrate gene alterations associated with predictive and prognostic outcomes in patients with metastatic colorectal cancer (mCRC) with polymerase chain reaction (PCR) and in‐house nextgeneration sequencing (NGS) to detect KRAS, NRAS, and BRAF mutations. In the present study, 41 patients with mCRC were assessed between August 2017 and June 2019 at a single institution. The overall concordance between NGS and PCR results for detecting KRAS, NRAS, and BRAF mutations was considerably high (87.8–92.7%), with only 15 discrepant results between PCR and NGS. Our companion diagnostic test analyzes KRAS, NRAS, and BRAF as a panel of CRC molecular targets; therefore, it has the advantages of requiring fewer specimens and being more time and cost efficient than conventional testing for separate analyses, allowing for the simultaneous analysis of multiple genes.

AB - Personalized treatments based on the genetic profiles of tumors can simultaneously optimize efficacy and minimize toxicity, which is beneficial for improving patient outcomes. This study aimed to integrate gene alterations associated with predictive and prognostic outcomes in patients with metastatic colorectal cancer (mCRC) with polymerase chain reaction (PCR) and in‐house nextgeneration sequencing (NGS) to detect KRAS, NRAS, and BRAF mutations. In the present study, 41 patients with mCRC were assessed between August 2017 and June 2019 at a single institution. The overall concordance between NGS and PCR results for detecting KRAS, NRAS, and BRAF mutations was considerably high (87.8–92.7%), with only 15 discrepant results between PCR and NGS. Our companion diagnostic test analyzes KRAS, NRAS, and BRAF as a panel of CRC molecular targets; therefore, it has the advantages of requiring fewer specimens and being more time and cost efficient than conventional testing for separate analyses, allowing for the simultaneous analysis of multiple genes.

KW - metastatic colorectal cancer

KW - next‐generation sequencing

KW - polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=85128674787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128674787&partnerID=8YFLogxK

U2 - 10.3390/cimb44040106

DO - 10.3390/cimb44040106

M3 - Article

AN - SCOPUS:85128674787

SN - 1467-3037

VL - 44

JO - Current Issues in Molecular Biology

JF - Current Issues in Molecular Biology

IS - 4

M1 - 1563

ER -

Comparison of Next‐Generation Sequencing and Polymerase Chain Reaction for Personalized Treatment‐Related Genomic Status in Patients with Metastatic Colorectal Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this